Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).
Conditions
Interventions
HSK31679 80mg
HSK31679 160mg
+1 more
Locations
1
China
Beijing Tsinghua Changgung Hospital, Tsinghua University
Beijing, China
Start Date
January 5, 2024
Primary Completion Date
December 12, 2025
Completion Date
January 16, 2026
Last Updated
February 11, 2026
NCT03151473
NCT02754037
NCT05989711
NCT00666016
NCT02653300
NCT05727644
Lead Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions